Institute of Mental Health

Belkins
The Institute of Mental Health (IMH) is a 2,000-bed acute tertiary psychiatric hospital situated on a 23-hectare campus at Buangkok Green Medical Park. Set amidst serene surroundings, IMH offers a comprehensive range of psychiatric, rehabilitative and counselling services for children, adolescents, adults, and the elderly.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

CONTROLANT NOW PROVIDING MONITORING AND SUPPLY CHAIN VISIBILITY FOR PFIZER-BIONTECH COVID-19 VACCINE'S GLOBAL DISTRIBUTION

Controlant | December 16, 2020

news image

Controlant, an leader in real-time supply chain monitoring and perceivability technologies for vigorously controlled ventures, for example, pharmaceuticals and life sciences and food and drink areas, today reported it is giving observing and Supply Chain Visibility administrations to Pfizer, comparable to the conveyance of Pfizer's mRNA-based Pfizer-BioNTech COVID-19 vaccine's worldwide circulation. In addition to the visibility and monitoring arrangements that Controlant ...

Read More

INDUSTRIAL IMPACT

QUANTUM GENOMICS SIGNS AN EXCLUSIVE LICENSE AND PRODUCTION AGREEMENT WITH GULF PHARMACEUTICALS INDUSTRIES JULPHAR

Quantum Genomics | December 06, 2021

news image

Quantum Genomics, a biopharmaceutical company specializing in the development of first-in-class drugs directly targeting the brain to treat complex/resistant hypertension, has announced the signing of an exclusive license and production agreement with Julphar to market and produce firibastat in the Middle East, all African countries, Commonwealth of Independent States and Turkey. A pharmaceutical company based in the United Arab Emirates and leader in the MENA region, Julphar will...

Read More

STEM CELL MODELS OF HUMAN SPINE DEVELOPMENT UNVEILED

Drug Target Review | January 15, 2020

news image

Scientists have created the first lab-dish models of the cellular clock, where each ‘tick’ stimulates the formation of the vertebra, which uses stem cells derived from adult human tissue. Over 20 years ago, Olivier Pourquié’s lab at Harvard University, US discovered a cellular clock in chicken embryos where each ‘tick’ stimulates the formation of a structure called a somite that ultimately becomes a vertebra. Now, Pourquié has led one of two teams to c...

Read More

CELL AND GENE THERAPY

BRAZIL’S SENAI CIMATEC DOSES FIRST HEALTHY VOLUNTEERS IN PHASE 1 TRIAL OF HDT BIO’S RNA COVID-19 VACCINE

HDT Bio Corp. | January 17, 2022

news image

HDT Bio Corp., a U.S. developer of immunotherapies for oncology and infectious diseases and SENAI CIMATEC, an important Brazilian education, research, and innovation institute, have dosed the first healthy volunteers in Brazil in a Phase 1 trial of HDT Bio’s RNA COVID-19 vaccine, HDT-301. SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT. The vaccine uses HDT Bio’s proprietary lipid nanoparticle RNA-delivery technology. Read More

news image

MEDICAL

CONTROLANT NOW PROVIDING MONITORING AND SUPPLY CHAIN VISIBILITY FOR PFIZER-BIONTECH COVID-19 VACCINE'S GLOBAL DISTRIBUTION

Controlant | December 16, 2020

Controlant, an leader in real-time supply chain monitoring and perceivability technologies for vigorously controlled ventures, for example, pharmaceuticals and life sciences and food and drink areas, today reported it is giving observing and Supply Chain Visibility administrations to Pfizer, comparable to the conveyance of Pfizer's mRNA-based Pfizer-BioNTech COVID-19 vaccine's worldwide circulation. In addition to the visibility and monitoring arrangements that Controlant ...

Read More
news image

INDUSTRIAL IMPACT

QUANTUM GENOMICS SIGNS AN EXCLUSIVE LICENSE AND PRODUCTION AGREEMENT WITH GULF PHARMACEUTICALS INDUSTRIES JULPHAR

Quantum Genomics | December 06, 2021

Quantum Genomics, a biopharmaceutical company specializing in the development of first-in-class drugs directly targeting the brain to treat complex/resistant hypertension, has announced the signing of an exclusive license and production agreement with Julphar to market and produce firibastat in the Middle East, all African countries, Commonwealth of Independent States and Turkey. A pharmaceutical company based in the United Arab Emirates and leader in the MENA region, Julphar will...

Read More
news image

STEM CELL MODELS OF HUMAN SPINE DEVELOPMENT UNVEILED

Drug Target Review | January 15, 2020

Scientists have created the first lab-dish models of the cellular clock, where each ‘tick’ stimulates the formation of the vertebra, which uses stem cells derived from adult human tissue. Over 20 years ago, Olivier Pourquié’s lab at Harvard University, US discovered a cellular clock in chicken embryos where each ‘tick’ stimulates the formation of a structure called a somite that ultimately becomes a vertebra. Now, Pourquié has led one of two teams to c...

Read More
news image

CELL AND GENE THERAPY

BRAZIL’S SENAI CIMATEC DOSES FIRST HEALTHY VOLUNTEERS IN PHASE 1 TRIAL OF HDT BIO’S RNA COVID-19 VACCINE

HDT Bio Corp. | January 17, 2022

HDT Bio Corp., a U.S. developer of immunotherapies for oncology and infectious diseases and SENAI CIMATEC, an important Brazilian education, research, and innovation institute, have dosed the first healthy volunteers in Brazil in a Phase 1 trial of HDT Bio’s RNA COVID-19 vaccine, HDT-301. SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT. The vaccine uses HDT Bio’s proprietary lipid nanoparticle RNA-delivery technology. Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us